Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ranjana H

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Updates in Treatment Strategies for Hodgkin LymphomaRanjana H Advani
Therapeutic Advances in Hematology|November 1, 2014
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibAmin Aalipour, Ranjana H Advani
British Journal of Haematology|October 12, 2013
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasAmin Aalipour, Ranjana H Advani
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CTRyan C Lynch, Ranjana H Advani
Hematology/Oncology Clinics of North America|February 7, 2026
Management of Classic Hodgkin Lymphoma in PregnancyMichael A Spinner, Ranjana H Advani
Hematology. American Society of Hematology. Education Program|December 4, 2018
Risk-adapted therapy for advanced-stage Hodgkin lymphomaMichael A Spinner, Ranjana H Advani
Clinical Advances in Hematology & Oncology : H&O|February 12, 2009
Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategiesAsh A Alizadeh, Ranjana H Advani
Current Opinion in Oncology|July 17, 2009
The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphomaLauren S Maeda, Ranjana H Advani
Case Reports in Oncology|October 27, 2017
Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88<sup>L265P</sup> MutationRyan C Lynch, Ranjana H Advani
Expert Opinion on Emerging Drugs|April 27, 2024
Emerging immunotherapies in the Hodgkin lymphoma armamentariumMichael A Spinner, Ranjana H Advani
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Updates in Treatment Strategies for Hodgkin LymphomaRanjana H Advani
Therapeutic Advances in Hematology|November 1, 2014
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibAmin Aalipour, Ranjana H Advani
British Journal of Haematology|October 12, 2013
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasAmin Aalipour, Ranjana H Advani
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CTRyan C Lynch, Ranjana H Advani
Hematology/Oncology Clinics of North America|February 7, 2026
Management of Classic Hodgkin Lymphoma in PregnancyMichael A Spinner, Ranjana H Advani
Hematology. American Society of Hematology. Education Program|December 4, 2018
Risk-adapted therapy for advanced-stage Hodgkin lymphomaMichael A Spinner, Ranjana H Advani
Clinical Advances in Hematology & Oncology : H&O|February 12, 2009
Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategiesAsh A Alizadeh, Ranjana H Advani
Current Opinion in Oncology|July 17, 2009
The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphomaLauren S Maeda, Ranjana H Advani
Case Reports in Oncology|October 27, 2017
Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88<sup>L265P</sup> MutationRyan C Lynch, Ranjana H Advani
Expert Opinion on Emerging Drugs|April 27, 2024
Emerging immunotherapies in the Hodgkin lymphoma armamentariumMichael A Spinner, Ranjana H Advani
Pageof 17